Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ruboxistaurin · 2 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Ruboxistaurin mesylate | DRUG | - |
Inclusion Criteria: * Patients must have type I or type II Diabetes Mellitus. * Have clinically diagnosed positive sensory symptoms such as numbness, lancinating pain, burning pain, aching pain, allodynia and prickling sensation that have been present not greater than 5 years but stable for 6 month...
Ruboxistaurin is an investigational small molecule being studied for the treatment of diabetic neuropathies, specifically symptomatic peripheral neuropathy in patients with diabetes. It is being developed by Eli Lilly and Company and has completed Phase 3 clinical trials.
Ruboxistaurin is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker LLY. The drug is an investigational small molecule intended for the treatment of diabetic neuropathies.
Ruboxistaurin is in Phase 3 clinical development. Two Phase 3 trials have been completed, each evaluating the drug for the treatment of peripheral neuropathy in patients with diabetes. The drug remains investigational and is not yet approved.
Ruboxistaurin has been studied in two completed Phase 3 trials. NCT00044395 enrolled 200 participants with diabetic neuropathies, and NCT00044421 enrolled 400 participants with diabetic neuropathies. Both trials were randomized, double-blind, and uncontrolled, with a combined enrollment of 600 participants.
Ruboxistaurin is not known by any alternative names. It is a distinct investigational small molecule developed by Eli Lilly and Company for the treatment of diabetic neuropathies. No other names for this drug have been reported.